NCT04075318View on ClinicalTrials.gov

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Parkinson's DiseaseParkinsonism
Interventions
BIOLOGICAL

UB-312

A synthetic peptide-based vaccine

BIOLOGICAL

Placebo

Matching placebo

Trial Locations (1)

Unknown

Centre for Human Drug Research, Leiden

Sponsors

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Centre for Human Drug Research, Netherlands

OTHER

collaborator

Worldwide Clinical Trials

OTHER

collaborator

Vaxxinity, Inc.

INDUSTRY

lead

United Neuroscience Ltd.

INDUSTRY